Company Description

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers.

Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.

The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2.

Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Day One Biopharmaceuticals, Inc.

Country	United States
Founded	2018
IPO Date	May 27, 2021
Industry	Biotechnology
Sector	Healthcare
Employees	155
CEO	Jeremy Bender

Contact Details

Address: 2000 Sierra Point Parkway, Suite 501 Brisbane, California 94005 United States
Phone	650 484 0899
Website	dayonebio.com

Stock Details

Ticker Symbol	DAWN
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$16.00
CIK Code	0001845337
CUSIP Number	23954D109
ISIN Number	US23954D1090
Employer ID	83-2415215
SIC Code	2834

Key Executives

Name	Position
Jeremy Bender	Chief Executive Officer
Charles York	Chief Financial Officer
Charles York	Chief Operating Officer

Latest SEC Filings

Date	Type	Title
Jan 13, 2025	8-K	Current Report
Jan 10, 2025	S-8	Securities to be offered to employees in employee benefit plans
Nov 20, 2024	8-K	Current Report
Nov 18, 2024	144	Filing
Nov 18, 2024	144	Filing
Nov 14, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024	144	Filing
Nov 7, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Nov 7, 2024	SC 13G	Statement of acquisition of beneficial ownership by individuals
Oct 31, 2024	144	Filing

View All SEC Filings